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Neovascularization is a hallmark of tumor growth. The newly formed blood vessels supply the proliferating tumor cells with nutrients and oxygen. Endothelial cells are central in this neovascularization process. They respond to the hypoxic conditions by migration into the hypoxic area, proliferation, and blood vessel support cell recruitment that eventually leads to stabilization of the newly formed vessel. Furthermore, they continuously recruit leukocytes from the circulation that in turn can stimulate neovascularization. Considering their central role in these processes and their direct accessibility for drugs via the blood circulation, tumor vascular endothelial cells are important target cells for therapeutic intervention in cancer.
This review will address new advances in the development of vascular drug-targeting approaches drugs. Drugs in this respect include pharmacologically active substances such as therapeutic genes, siRNAs, antisense oligodeoxynucleotides, chemotherapeutics, toxic molecules, and chemical inhibitors of signal transduction. Increase in efficacy and / or reduction in toxicity is achieved by incorporating the drug in a carrier or vehicle. The carrier selectively binds to the target cells by virtue of intrinsic specificity, or incorporation of homing ligands with selectivity for the target epitopes. AĞer binding, internalization of carrier-complexed drug will be followed by intracellular drug release, although in some instances extracellular delivery will suffice for the effect (Fig. 1) . The behaviour of the carrier molecules largely determines the pharmacokinetic behaviour and cellular distribution of the drug. Furthermore, selective delivery of the drug into the target cells may allow achievement of higher drug concentrations in the target cells or even in specific compartments of the target cells. As a result, drug efficacy can be enhanced. With the advent of powerful molecular biological techniques, molecular mechanisms of disease become unravelled at a fast pace. As a result, new chemical and biotechnological entities are generated that in principle can exert potent effects on disease processes but may have deficient bio-stability or distribution to the areas of disease. In addition, they oĞen exert strong toxicity upon geĴing access to healthy tissue. Furthermore, the chemical characteristics of these new compounds may be such that their access to the site of action, in particular to intracellular target enzyme systems, is minimal. By covalently aĴaching them to or incorporating into carrier molecules, the whole body and cellular disposition of these drugs can be considerably manipulated (Molema & Meĳer, 2001) .
Carriers can be divided in particle-type, soluble and cellular carriers. Particle-type carriers include liposomes, lipid particles (low and high density lipoproteins, LDL and HDL, respectively), microspheres and nanoparticles, and polymeric micelles. Soluble carriers comprise monoclonal antibodies and fragments thereof, modified plasma proteins, peptides, polysaccharides, and biodegradable carriers consisting of polymers of various chemical composition. For the site-selective delivery of genes, vectors such as liposomes, lipid complexes, polymers and viruses are exploited. In some cases, immune effector cells and stem cells have been employed as vehicles to specifically deliver effector activities to the target tissue. In Fig. 2 , an overview of the most frequently used carrier molecules studied as treatment modalities in tumor vascular drug-targeting strategies is given.
In general, carrier molecules are modified with targeting ligands that specifically bind to target epitopes on the tumor endothelial cells, harnessing the construct with cell specificity. Although untargeted constructs can accumulate in extravascular spaces in tumor tissue due to locally enhanced permeability (Maeda et al., 2000) , the focus of this review will be on constructs that actively target and deliver drugs to or into tumor endothelial cells. Monoclonal antibodies harbor intrinsic specificity for a target epitope, yet have the disadvantage of low drug loading capacity while maintaining antigen binding and pharmacokinetic characteristics. Therefore, they are oĞen used as targeting ligands by coupling them to carriers with high drug-loading capacity (Everts et al., 2003; Kok et al., 2001) . The use of peptide and antibody fragment expressing phage display libraries has led to the identification of molecules that specifically bind to tumor endothelial cells without the requirement of knowing the identity of the target epitope (Mutuberria et al., 2001 ). An advantage of peptide-based ligands over antibody fragments is that the former ones oĞen bind in a species-independent way to their target molecules. Antibodies raised against, e.g., adhesion molecules, in contrast, frequently do not cross-react with similar structures of different species (Schraa et al., 2002a) . The major advantage of this cross-species recognition is that it The drug-carrier complex binds to epitopes on the target cells due to its intrinsic specificity for the target or due to specificity created by homing ligands such as peptides and antibodies. Upon binding, the drug-carrier construct is either internalized (leĞ) or stays at the outside of the cells (right). In the case of internalization, the transport via early endosomes into lysosomes will lead to drug-carrier construct degradation, either as a result of pH drop or as a result of enzymatic degradation. The drug is released into the cytoplasm, aĞer which it can find its molecular target in the cell or redistribute to the cell's exterior. When the target epitope is a non-internalizing epitope, the activity of the targeted drug will be at the outside of the cell. Examples of the drug-targeting approaches that require internalization are delivery of toxins, plasmids, and apoptosis-inducing compounds. For the delivery of cytolytic activity to kill tumor endothelium and of blood coagulation inducing factors, the non-internalizing route suffices (from Schraa et al., 2002a) .
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Tumor vascular endothelium-directed drug-targeting facilitates the step from pre-clinical to clinical testing of drug-targeting constructs.
To choose the proper target and the proper pharmacological entity for inclusion in drug-targeting constructs, knowledge on the molecular control of endothelial behavior during tumor-induced angiogenesis is essential. Therefore, a short description of the cellular and molecular processes involved in those events is given.
ENDOTHELIAL CELL FUNCTION IN NORMAL PHYSIOLOGICAL PROCESSES
The blood vessels in our body are highly heterogeneous with regard to architecture and function. The larger blood vessels consist of endothelial cells, smooth muscle cells, connective tissue and elastic elements, and are mainly responsible for transporting blood through the body. The endothelium in larger vessels is actively involved in blood pressure control via, among others, release of the vasodilator prostacyclin and the vasorelaxant nitric oxide (NO) as well as the production of vasoconstrictors including endothelin-1 and the arachidonic acid metabolites thromboxane A2 and prostaglandin H2 (Vane et al., 1995) . In contrast, in the microvascular, capillary bed of organs, the endothelial cells reside on a basal lamina and are only supported by sparsely distributed pericytes that facilitate vessel maturation and vascular integrity (Hellstrom et al., 2001) .
Endothelial cells exert four main functions. They serve as a (semipermeable) barrier to transport of soluble molecules and maintain haemostatic balances via the production of anti-coagulants such as thrombomodulin, tissue factor pathway inhibitor, and procoagulants including von Willebrand factor and tissue factor. Other factors including thrombin, antithrombin and heparan sulfate proteoglycans, platelet activating factor and platelet factor-4 also play a prominent role in haemostatic control by the vessel wall in conditions of physical damage and cellular stress (Vane et al., 1995) .
Coordinated recruitment of leukocytes into underlying tissue as a result of an inflammatory insult is another essential task of endothelial cells (Von Andrian & Mackay 2000; Pober, 2002) . This process takes place in the postcapillary venules in microvascular beds of all organs (except the spleen, lungs and liver), aĞer activation of endothelial cells by pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α and Interleukin (IL)-1β.
The last process in which endothelial cells play a prominent role is new blood vessel formation or angiogenesis. During angiogenesis a complex interplay between endothelial cells, smooth muscle cells and/or pericytes, fibroblasts and leukocytes takes place. Angiogenesis occurs during many physiological processes in the body, including wound healing and placental growth during pregnancy. In chronic inflammatory diseases, angiogenesis provides the tissue with a means to facilitate ongoing leukocyte recruitment and supply sufficient amounts of oxygen and nutrients to support continuous cellular activation and cell death induction (Paleolog, 2002; Fearon et al., 2003) . In growing tumors, hypoxic conditions and/or disbalance in the production of pro-and anti-angiogenic factors via oncogenic transformation of tumor cells are conditions that activate the capillary bed endothelial cells to become pro-an- (Bergers & Benjamin, 2003) . A direct relation between leukocyte-endothelial cell interactions in the control of (tumor) angiogenesis has also been implicated in various studies (Reinders et al., 2003; Voronov et al., 2003) .
MOLECULAR CONTROL OF TUMOR ANGIOGENESIS
Tumor angiogenesis differs significantly from normal angiogenesis. The vascular network in growing tumors is structurally and functionally abnormal, with tortuous, dilated blood vessels, aberrant blood flow and hyper-permeable regions. Within the network, the endothelium is highly heterogeneous with respect to activation status, as exemplified by differential expression of vascular markers, and vessel maturation is delayed (Bergers & Benjamin, 2003) .
Tumor blood vessels can form from pre-existing vessels by angiogenic sprouting or by intussusceptive growth. In addition, circulating endothelial progenitors can contribute to tumor angiogenesis (Carmeliet & Jain, 2000) . During angiogenic sprouting, the process that has been most extensively studied, endothelial cell activation, migration and proliferation take place in a highly orchestrated manner. Blood vessel maturation occurs via migration and support of pericytes and local changes in growth factor composition.
The switch to the angiogenic phenotype involves a change in balance between pro-and antiangiogenic factors which can occur at any stage of tumor progression. Vascular endothelial growth factor (VEGF) is quickly produced by tumor cells as a result of hypoxia or oncogenic transformation but can also be locally delivered by leukocytes. It signals mainly through VEGF receptor (VEGFR)-2 to activate a network of kinases and other downstream effectors, leading to endothelial cell migration, proliferation and survival (Ferrara et al., 2003) . The importance of VEGF for angiogenesis control was shown more than a decade ago in a pre-clinical study where administration of VEGF neutralizing antibodies resulted in strong inhibition of tumor outgrowth (Kim et al., 1993) . Recently, its potential as a target for anti-angiogenic cancer therapy was also demonstrated in the clinic (Hurwitz et al., 2004; WilleĴ et al., 2004) .
VEGF-R2 based induction of inducible NO synthase (iNOS) activity is considered to be essential in early stage vessel dilation, which likely acts in conjunction with the release of VE-cadherin from its actin anchor, leading to increased endothelial permeability (Weis et al., 2004) . Subsequently, the basement membrane of the capillary bed is degraded by matrix metalloproteinases (MMPs), allowing serum components to leak out of the vessel and to form a provisional matrix onto which endothelial cells can migrate into the tissue.
Upon hypoxia, local angiopoietin (Ang)-2 production is also increased, as a result of which it can compete with Ang-1 for their mutual Tie-2 receptor. Consequently, the endothelial cells become responsive to growth factors (Ramsauer & D'Amore, 2002) . Besides induction of its ligand, Tie-2 receptor expression can also be modulated by hypoxia (Willam et al., 2000) . During the course of neovessel formation, prevention of endothelial apoptosis is effected by VEGF-R2 as well as αvβ3 integrin-mediated signal transduction (Stromblad et al., 1996) . Furthermore αvβ3 integrin ligation upregulates MMP-2 to induce endothelial cell invasion (SilleĴi et al., 2001) AĞer cellular proliferation, functional blood vessels should form. Maturation of the newly formed vessels is controlled via the recruitment of pericytes and the formation of new extracellular matrix components. This process is also tightly controlled by the spatiotemporal expression of cytokines, growth factors and their respective receptors, with the main factors involved being platelet derived growth factor, transforming growth factor-β, Ang-1 and sphingosine-phosphate (Jain, 2003) . Furthermore, during the different stages of angiogenesis, different basement membrane components actively regulate endothelial cell responses (Kalluri, 2003) .
TARGET EPITOPES ON TUMOR ENDOTHELIAL CELLS
One of the main determinants of the therapeutic success of drug-targeting is the selectivity of the cellular target molecule in combination with the homing ligand in the targeting construct. In theory, any protein expressed in the membrane of the tumor endothelial cells can serve as a target provided it is absent from other cells in the body. The first molecular targets on tumor endothelial cells were identified while unravelling endothelial cell behavior during the neovascularization process. Later on, the search for targets moved toward investigations using methods like phage display (RajoĴe et al., 1998) and serial analysis of gene expression or SAGE (St Croix et al., 2000) , for which no prior knowledge of the target epitope identity or function is required. In Table 1 , putative target epitopes on tumor endothelial cells reported in the last two decades are summarized.
Based on a detailed understanding of the function of the molecules during normal physiological and pathophysiological conditions, they can be selected as a target for further study for vascular drug-targeting. Essential in this respect is knowledge on their expression paĴerns in other vascular beds and on other cells in the body. By this means, one can either ensure selectivity of the target or
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Tumor vascular endothelium-directed drug-targeting identify the places in the body where potential side effects can occur. Furthermore, knowledge regarding cellular handling aĞer ligand binding is essential, as it determines the choice of effector molecules to be delivered. In the case of using, e.g., bacterial toxins, toxic drugs, or plasmids encoding therapeutic proteins, intracellular delivery is a prerequisite, as their effects are exerted in the cells' interior. This implies that the target epitope needs to be internalized upon binding of the drug-targeting construct. In contrast, for blockade of tumor blood flow by selective delivery of a blood coagulation-inducing protein or by cytotoxic T lymphocyte-mediated killing of the tumor endothelium, delivery of the effector at the outer membrane of the tumor endothelium suffices.
TARGETED TUMOR INFARCTION
In general, tumor vasculature-directed therapies either aim at tumor blood flow inhibition, interference with endothelial angiogenic behaviour, or at the direct induction of tumor endothelial cell death. Interference with angiogenic signal transduction pathways oĞen indirectly leads to endothelial cell death due to apoptosis induction. The therapeutic potentials of approaches aiming to interfere with the blood supply can be easily appreciated when considering the fact that in tumors oĞen hundreds of tumor cells are fed by only a few blood vessels (Fig. 3) . The number of endothelial target cells is limited, in contrast to the number of tumor cells to be killed by a tumor cell-directed approach. Furthermore, accessibility of the tumor endothelium is significantly beĴer compared to that of tumor cells, with many layers of tumor cells being oĞen nurtured by only one blood vessel. HiĴing the tumor at the level of its blood supply is therefore considered as hiĴing the tumor at its most vulnerable component. The following sections focus on targeted delivery of effector molecules that are able to block tumor blood flow, either by induction of blood coagulation in the tumor blood vessels or induction of tumor endothelial cell death.
One of the first papers demonstrating the potential of tumor endothelial cell killing and consequent local blood flow blockade to inhibit tumor outgrowth employed immunotoxins aimed at an artificially upregulated target on mouse tumor endothelium, major histocompatibility complex (MHC) class II (Burrows & Thorpe, 1993) . In the same tumor model, MHC class II antibody mediated delivery of a truncated form of the activator of the extrinsic pathway of blood coagulation, tissue factor, led to a massive debulking of large tumor masses (Huang et al., 1997) . These proof-of-concept studies supported the hypothesis put forward more than three decades ago that selectively interfering with the tumor blood supply would lead to strong anti-tumor effects. While the studies referred to above were executed in mice in which the tumor (endothelial) cells were genetically altered to provide suitable targets, these were rapidly followed by new studies employing endogenous targets on tumor endothelial cells.
Both the anti-vascular cell adhesion molecule (VCAM)-1 antibody-targeted truncated tissue factor study (Ran et al., 1998) and the anti-EDB oncofetal domain of fibronectin (EDB-Fn) antibody domaintargeted tissue factor study (Nilsson et al., 2001) corroborated the data on the therapeutic efficacy of the first local tumor infarction studies. Of importance is that the success of the so called coaguligand strategies was strongly dependent on the percentage of tumor blood vessels that became infarcted. In an elegant study, Hu and colleagues (2003) compared the therapeutic potency of three recombinant fusion proteins consisting of truncated tissue factor and antibodies against either DNA expressed in degenerative areas, or fibronectin in the tumor vessel basement membrane, or an arginine-glycine-aspartic acid (RGD) sequence specific for αv integrins (see below). Interestingly, while fibronectin-and αv-targeted tissue factor induced thrombosis in small and medium Abbreviations used: EDB-Fn, EDB-oncofetal domain of fibronectin; MMP, matrix metalloproteinase; TEM, tumor endothelial marker; VEGF(R), vascular endothelial cell growth factor (receptor).
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G. Molema sized vessels, DNA-targeted tissue factor did so in larger vessels. Combining all three coaguligands was the most effective treatment strategy to inhibit tumor outgrowth. Since in many tumors endothelial heterogeneity at different stages of tumor growth is likely cause of lack of therapeutic success of a monotarget therapy, a multi-target approach seems to be indicated for further development.
TARGETED TUMOR ENDOTHELIAL CELL KILLING
Another seminal study showing the therapeutic potential of killing tumor vascular endothelium used two different mouse tumor models. In one model the enzyme thymidine kinase was selectively expressed in tumor endothelium, whereas in the other model this enzyme was expressed in tumor cells only. Subsequent treatment with Ganciclovir induced cytotoxicity in the endothelial cells and in the tumor cells, respectively. It was shown that the anti-tumor effects of killing the endothelium, representing only 5% of the cell volume in the tumor tissue, were similar to the effects of killing 50% of the tumor cells (Mavria & Porter, 2001) .
To date, αvβ3 integrin, VEGF-Rs and the EDB domain of fibronectin have been extensively studied as targets for the delivery of toxic drugs into tumor endothelial cells. Without trying to be comprehensive, some of the studies reported are briefly discussed below.
RGD-based approaches
Chemically constrained RGD-peptides preferentially bind αvβ3/αvβ5 integrin expressed on proliferating tumor endothelial cells, besides their intrinsic binding specificity for αvβ3 on macrophage subsets in liver and spleen. When conjugated to the chemotherapeutic drug doxorubicin or the apoptosis inducing peptide (KLAKLAK) 2, strong anti-tumor effects could be brought about in vivo Ellerby et al., 1999) .
To obtain an αvβ3/αvβ5 specific macromolecular carrier protein with high drug loading capacity and improved pharmacokinetic behavior, we chemically conjugated cRGDfK peptides to a 150 kDa immunoglobulin protein backbone. The multivalent derivatives displayed a more than 1200-fold increased affinity for αvβ3/αvβ5 integrins on endothelial cells when the peptide : protein ratio was about 22:1 (Kok et al., 2002) . Using this approach, we constructed RGD-anti-CD3 antibodies that could redirect the cell killing activity of cytotoxic T lymphocytes to proliferating endothelium (Schraa et al., 2004) . The thus created macromolecular RGD-proteins exhibited improved pharmacokinetic behavior, as reflected by a plasma half life in mice of approximately 90 min. In s.c. tumors in mice, the RGD-protein conjugates selectively localized at the tumor vascular endothelium (Schraa et al., 2002b) .
Similar targeting strategies were employed for gene delivery purposes. High molecular mass polymeric conjugates of an RGD-peptide and a cationic polymer complexed with a plasmid encoding a mu- A. Many tumors consist of numerous layers of tumor cells fed by one blood vessel. By selectively interfering with blood vessel function via, e.g., the induction of local blood coagulation, hundreds of tumor cells will be deprived of oxygen and nutrients, as a result of which they will die (adapted from Denekamp, 1984) . B. Selective delivery of truncated tissue factor, a blood coagulation inducing factor, locally at the tumor vascular endothelial membrane in mice, completely infarcted blood vessels in the tumor (asterisk denotes a tissue factor induced fibrin clot in a blood vessel filled with erythrocytes). As a result, several layers of tumor cells (arrow head) were killed within 24 h aĞer treatment (unpublished, see Huang et al., 1997 for experimental details). Tumor cells fed by blood vessels in which the endothelium did not express the target epitopes were not affected (arrow). For therapeutic success, the majority of tumor vessels should become infarcted.
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Tumor vascular endothelium-directed drug-targeting tant Raf protein inhibiting endothelial cell survival signalling, or with siRNA specifically knockingdown VEGFR-2 expression, induced tumor regression and inhibition of tumor outgrowth, respectively (Hood et al., 2002; Schiffelers et al., 2004) .
VEGF-based approaches
Angiotoxins are therapeutics consisting of angiogenesis-related carrier molecules conjugated to toxin molecules. One example of angiotoxins developed for the selective killing of tumor endothelial cell is the group comprising VEGF as a carrier molecule. Upon binding to VEGF-R2 over-expressed on tumor neovasculature, the VEGF/VEGF-R complex is internalized. This makes VEGF protein a suitable carrier for the intracellular delivery of pharmacologically active drugs or toxins. Both chemical conjugates of diptheria toxin (DT) and VEGF protein (Olson et al., 1997) , and recombinant fusion proteins of VEGF 165 or VEGF 121 and DT translocation and enzymatic domain (Arora et al., 1999) have been reported.
Cell therapy to selectively kill tumor endothelial cells via VEGF specificity has been aĴempted in different ways. By immunizing mice with dendritic cells pulsed with soluble VEGF-R2, the animals developed both an antibody and a cytotoxic T lymphocyte response to VEGF-R2. As a consequence, tumor induced angiogenesis was blocked and development of pulmonary metastases could be prevented. Interestingly, in the immunized mice the cellular processes involved in wound healing were not affected (Li et al., 2002) .
By ex vivo transfecting cytotoxic T lymphocytes with a construct encoding the VEGF-T cell receptor zeta chain, the cytolytic activity was selectively redirected to VEGF-R2 expressing cells, leading to strong anti-tumor effects in vivo (Niederman et al., 2002) . The main advantages of redirecting cellular therapy to tumor endothelial cells instead of to tumor cells as employed in earlier immunotherapeutical approaches (Withoff et al., 2001) include beĴer accessibility of the target cells, a limited number of target cells to be killed, and the absence of immunosuppressive conditions locally at the level of the endothelium.
EDB-Fn domain-targeted approaches
Fibronectin is an extracellular matrix component. The fibronectin isoform containing type III repeat extradomain B (EDB-Fn) is a marker of angiogenesis, with endothelium invading the tumor tissue migrating along extracellular matrix fibers containing EDB-Fn. Recombinant-technology-derived fusion proteins of a single chain antibody variable fragment (ScFv) directed against EDB-Fn with mouse TNFα exhibited in vivo stronger anti-tumor activity than TNFα itself. This effect was further enhanced by combination treatment with the fusion protein and the chemotherapeutic drug melphalan (Borsi et al., 2003) . In a similar way, Interleukin-2 (IL-2)-ScFv fusion proteins were prepared. Following administration in vivo, the fusion protein localized at the site of the tumor vessels, resulting in an increase in leukocyte infiltration into the tumor tissue and massive tumor cell death. Whether the targeted IL-2 also exerted a direct cytotoxic effect on the endothelial cells in the tumor could not be unequivocally established in those studies (Carnemolla et al., 2002) . Of interest was the observation that the physicochemical properties of ScFvs recognizing EDB-Fn strongly affected the homing potential. Extreme isoelectric point values of < 5 and > 9 of those ScFvs inhibited protein extravasation, possibly by virtue of electrostatic interaction with the endothelium or extracellular matrix components (Melkko et al., 2002) 
CONCLUSIONS AND PERSPECTIVES
Tumor vascular drug-targeting strategies aimed at directly or indirectly blocking the tumor blood flow have proven their therapeutic potential in inhibiting tumor growth and reducing tumor mass in pre-clinical tumor models. Those studies have all been performed in different animal models, being either immunocompetent or immune deficient, with different tumors growing at different sites in the body. Until now, no concerted action has been undertaken to compare the different effector strategies within one model to evaluate the relative effectiveness of the treatments. The study by Hu and coworkers (2003) is one of the few that addressed the efficacy of the same effector delivered at different targets on subsets of tumor endothelium.
By targeting the endothelium, the main obstacle in tumor cell-directed therapies, the endothelial barrier, has been eliminated. Yet, the heterogeneity in tumor endothelial cell behavior within a clinically relevant tumor mass and between different tumors is a serious problem resulting from the concomitant presence of blood vessels in different angiogenic stages. Furthermore, the recently reported genetic abnormalities in tumor endothelial cells (Hida et al., 2004; Streubel et al., 2004) and the existence of mosaic tumor vessels in which endothelial cells and tumor cells form the luminal surface of the neovessels (Chang et al., 2000) may all contribute to the inferior responses to anti-vascular therapy in established tumors. Pre-clinical investigations on the anti-tumor efficacy of multi-target approaches in clinically relevant tumor masses are crucial for the rational development of successful clinical strategies for the future. A thorough inventory of the molecular basis of tumor vascular heterogeneity paralleled by immunohistochemical analyses of patient tumor biopsies for expression of target epitopes under study will be essential in this development.
